0.73 USD
▼-0.05-6.25%
盘后 0.74 +1.13%
2026-11-05
市值
$45.89M
市盈率
—
EPS
-1.19
股息率
—
52 周区间
0.71 – 3.82
成交量
434.52K
Beta
-0.18
目标价
6.00
52W 低 0.7152W 高 3.82
价格走势
公司简介
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Rα in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.